West Pharmaceutical Services Inc
F:WPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
West Pharmaceutical Services Inc
F:WPS
|
US |
|
S
|
Serco Group PLC
XMUN:SEO
|
UK |
|
SKY Perfect JSAT Holdings Inc
F:SKM
|
JP |
|
Sanki Engineering Co Ltd
TSE:1961
|
JP |
|
A
|
Arbor Realty Trust Inc
F:OWQ
|
US |
|
Y
|
Yue Da International Holdings Ltd
HKEX:629
|
HK |
|
P
|
Pfizer Inc
DUS:PFE
|
US |
|
A
|
Alma Media Oyj
XBER:A4M
|
FI |
|
W
|
Washington H Soul Pattinson and Company Ltd
SWB:WD3
|
AU |
|
S
|
Syzygy AG
XHAM:SYZ
|
DE |
West Pharmaceutical Services Inc
West Pharmaceutical Services makes the small but essential parts used to store, seal, and deliver injectable medicines. Its products include rubber stoppers, seals, syringe and vial components, and drug containment and delivery systems that help protect medicines from contamination and keep them usable from factory to patient. Its main customers are pharmaceutical and biotech companies that make injectable drugs and vaccines, along with contract manufacturers and other healthcare supply chain partners. West sells these components and related services into long-term supply relationships, so it earns money each time customers source packaging and delivery parts for their medicines. What makes West important is that it sits at a critical point in the injectable drug supply chain. Drug makers rely on its components to meet strict quality and sterility requirements, so the business is tied to regulated healthcare manufacturing rather than ordinary consumer demand. That makes West less about branding and more about being a trusted, behind-the-scenes supplier that helps biologic and injectable therapies reach patients safely.
West Pharmaceutical Services makes the small but essential parts used to store, seal, and deliver injectable medicines. Its products include rubber stoppers, seals, syringe and vial components, and drug containment and delivery systems that help protect medicines from contamination and keep them usable from factory to patient.
Its main customers are pharmaceutical and biotech companies that make injectable drugs and vaccines, along with contract manufacturers and other healthcare supply chain partners. West sells these components and related services into long-term supply relationships, so it earns money each time customers source packaging and delivery parts for their medicines.
What makes West important is that it sits at a critical point in the injectable drug supply chain. Drug makers rely on its components to meet strict quality and sterility requirements, so the business is tied to regulated healthcare manufacturing rather than ordinary consumer demand. That makes West less about branding and more about being a trusted, behind-the-scenes supplier that helps biologic and injectable therapies reach patients safely.
Strong start: West said first-quarter revenue and adjusted EPS came in well above expectations, with revenue of $845 million and adjusted EPS of $2.13.
Guidance raised: The company raised full-year 2026 organic revenue growth guidance back to 7% to 9% from 5% to 7%, and lifted adjusted EPS guidance to $8.40 to $8.75.
HVP strength: High-value product components were the main growth engine again, helped by biologics, GLP-1s, Annex 1-related upgrades, and better execution in Europe.
Margins improved: Gross margin rose to 35.1% and adjusted operating margin reached 21.4%, with management saying mix and operational execution should keep margins expanding.
Demand outlook: Management said it did not see pull-forward tied to Middle East tensions, and that rising oil and commodity costs should be offset through hedging, pricing, and other actions.
CEO transition: Eric Green said the company is actively searching for a successor and expects an appointment in the second half of 2026.
